ETOREAT® Research Progress Presentation at Two Medical Association Meetings in Japan

The MEDRx Group will give presentations about research progress involving ETOREAT® at the 31st Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan to be held on May 19 – 21, 2016 and the 32nd Annual Meeting of the Japan Society of Drug Delivery Systems to be held on June 30 and July 1, 2016. The MEDRx Group is working in the United States on the development of ETOREAT®, a topical patch for alleviating pain caused by inflammation.

About the 31st Annual Meeting of The Academy of Pharmaceutical Science and Technology, Japan

Time: Thursday, May 19, 2016 – Saturday, May 21, 2016
Venue: Nagaragawa Convention Center and Gifu Miyako Hotel
Sponsors: The Academy of Pharmaceutical Science and Technology, Japan
Theme: The world of new pharmaceutical formulation and creation derived along the clear stream
URL: http://www.congre.co.jp/apstj31/

The MEDRx presentation:

ETOREAT® is a topical patch that incorporates etodolac in the form of an ionic liquid. The ionic liquid format increases the water and fat solubility of etodolac. ETOREAT® has an in vitro skin permeability of etodolac that is 9.3 times higher than that of patches using only etodolac without an ionic liquid.

About the 32nd Annual Meeting of the Japan Society of Drug Delivery System

Time: Thursday, June 30, 2016 – Friday, July 1, 2016
Venue: GRANSHIP (Shizuoka Convention & Arts Center)
Sponsors: The Japan Society of Drug Delivery System
Theme: “Construction of a healthy longevity society through drug delivery systems”
URL: http://www.procomu.jp/dds32/

The MEDRx presentation:

ETOREAT® is a topical patch that incorporates etodolac in the form of an ionic liquid. Pharmacokinetics and efficacy tests using rats were performed. The results showed that ETOREAT® improves the skin absorption of etodolac and, as a result, the drug’s effectiveness.
ETOREAT®, a topical patch that incorporates etodolac, is the most important item in the MEDRx Group’s pipeline. This is expected to be the first finished product that uses the MEDRx ILTS® (Ionic Liquid Transdermal System). Development activities are proceeding in the United States with the goal of receiving approval to manufacture and sell ETOREAT® as a prescription drug.

Etodolac

Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that is used extensively worldwide as an oral treatment for pain and inflammation. MEDRx’s ETOREAT® is the world’s first attempt to develop a version for use as a patch.

in vitro

This term, which is derived from Latin, means “in an artificially created environment.” For this research project, the term is used to refer to tests performed by using pieces of skin from animals.

Contact:
MEDRx Co., Ltd.
Management Department
E-mail: info@medrx.co.jp

******************************************************************************